The global search for an effective coronavirus vaccine is still underway, as more than 57 million people have contracted the disease so far and more than 1.3 million have lost their lives from it. The pharmaceutical companies Pfizer and Moderna recently declared that their vaccine candidates have been successful in late-stage trials. Moderna claimed that its vaccine is 94.5% effective, Pfizer has said that its candidate has shown 95% efficacy.
Latest updates on covid vaccines
Oxford covid vaccine
Scientists at the University of Oxford hope to report the results of late-stage trials of their COVID-19 vaccine by Christmas. The Oxford research was held back by low infection rates over the summer, but Phase III trials are now accumulating the data needed to inform the results as a new surge in the pandemic hits countries around the world. Oxford is developing its vaccine together with pharmaceutical company AstraZeneca.
Covaxin covid vaccine
The third phase of testing of Covaxin manufactured in India will start from today in Haryana. Last month, Bharat Biotech had said that it had successfully completed the interim analysis of Phase 1 and 2 trials and is initiating Phase 3 trials.
On November 18, Vij volunteered to become the “first volunteer” for the phase III clinical trial of the vaccine.
Covaxin is being indigenously developed by Bharat Biotech in collaboration with the Indian Council for Medical Research (ICMR).
Modern covid vaccine
Stephane Bancel, CEO of Moderna Inc., whose vaccine was found to be 94.5% effective in a preliminary analysis of a large late-stage clinical trial, said more investment is needed in early testing. If so, vaccines could be created even faster.
Moderna CEO Stephane Bancel added that Moderna’s vaccine trial was on track to get the final results of its large trial in a week or so.
Pfizer covid vaccine
Pfizer Inc said Wednesday that the final results of the last stage of the trial of its Covid-19 vaccine show it was 95% effective, adding that it had the required two months of safety data and that it would request emergency clearance from USA In a few days.
The drugmaker said that the efficacy of the vaccine, developed with German partner BioNTech SE, was consistent across age and ethnic demographics, and that there were no major side effects, a sign that immunization could be widely used in all the world.
Oxford vaccine at cost ₹500
Serum Institute of India (SII) CEO Adar Poonawalla said Thursday that he could sell Covishield, the vaccine being developed by Oxford University, for around ₹500-600 per shot in the market vs. ₹220 per shot will cost the government. Poonawalla made this statement on the opening day of the Hindustan Times Leadership Summit (HTLS), where he was one of the speakers.
The Covid-19 vaccine will be ready soon
The Union’s health minister, Dr. Harsh Vardhan, on Thursday expressed confidence that a Covid-19 vaccine will be ready in the “next three to four months.” “followed by the elderly and people prone to disease.” Hopefully, 2021 should be a better year for all of us, “he further said.
Italy to start vaccination against coronavirus in January
Italy is set to receive 3.4 million doses of the vaccine from Pfizer in the second half of January through the European Union purchase program, enough to provide the necessary two doses to 1.6 million of the 60 million people Italy, said special commissioner Domenico Arcuri. He said that elderly Italians and those most at risk of exposure would have the first priority.
.
